Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment
SALT LAKE CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment.
“These studies demonstrate our ongoing commitment to excellence in scientific research and the rapid translation of this research into clinical care,” said Nicole Lambert, president, Myriad Genetics. “We appreciate the opportunity to collaborate with leaders in the industry at Mayo Clinic, Johns Hopkins, Cleveland Clinic, University of Pennsylvania and Dana Farber Cancer Institute to deliver products that provide precise and equitable care for women dealing with breast cancer risk and treatment options.”
Genomic Instability Scores to Guide Eligibility for Treatment with PARP Inhibitors
This study, with collaboration from researchers at Mayo Clinic and Johns Hopkins, assesses the differences in genomic instability score (GIS) thresholds for different types of breast cancer (triple-negative breast cancer and estrogen receptor-positive breast cancer) using the GIS for ovarian cancer as a comparator to guide the identification of potential candidates for treatment with PARP inhibitors.
Finding Ways to Improve Polygenic Risk Scores by Reducing Ancestral Bias
This study, done in collaboration with researchers from Cleveland Clinic, University of Pennsylvania, and Dana-Farber Cancer Institute, validates the integration of an ancestry-inclusive breast cancer polygenic risk score with a clinical and family history-based model in the development of a risk assessment tool that is both genomically-informed and equitable.
Follow Myriad on Twitter via @myriadgenetics and keep up to date with SABCS meeting news and updates by using the #SACBS21 hashtag.
About Myriad Genetics
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice, MyPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Prequel, Foresight, GeneSight, RiskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.
Safe Harbor Statement
Grand Opening Networking Reception in Expo Hall
Presentation Details TBA
â€œTime Machineâ€ - The Power of Petabyte Image Datalakes